A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation

Douglas E. Jorenby, Scott J. Leischow, Mitchell Nides, Stephen I. Rennard, Joseph A. Johnston, Arlene R. Hughes, Stevens S. Smith, Myra Muramoto, David M. Daughton, Kimberli Doan,

New England Journal of Medicine · 1999 · 1.6K citations · 21 references

DOIFull text

Open access

Concepts

TL;DR

Nicotine‑replacement therapies and the antidepressant bupropion are established aids for smoking cessation. In a double‑blind, placebo‑controlled trial, 903 smokers received sustained‑release bupropion, a nicotine patch, both, or placebo over nine weeks of medication and eight weeks of patch therapy, with a target quit day of week 2.

Abstract

Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clinical depression were excluded. Treatment consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo. The target day for quitting smoking was usually day 8.

References

21